Investigators analyze 4-day food records and supplement reports from 285 patients at seven Swedish metabolic and bariatric centers in a substudy of the randomized BEST trial.
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.